Retatrutide: What TRIUMPH-1 Showed (and Why You Cannot Get It Yet)
Retatrutide is an investigational obesity drug. It is not FDA-approved and is not available at any clinic. Here is what the data shows, in plain language, and what you can actually start now.
What is retatrutide?
Retatrutide is an experimental, once-weekly injectable being developed by Eli Lilly for obesity. It is the most-watched name in the obesity-drug pipeline because of unusually large weight-loss figures in mid-stage and late-stage research. It is important to be clear up front: retatrutide is investigational. It is not approved by the FDA, it is not sold by any pharmacy or clinic, and New Hope Weight Loss does not offer it.
How is it different from semaglutide and tirzepatide?
Semaglutide acts on one hormone pathway (GLP-1). Tirzepatide acts on two (GIP and GLP-1). Retatrutide is designed to act on three at once: GIP, GLP-1, and glucagon. The glucagon component is thought to raise energy expenditure in addition to reducing appetite. More pathways is not automatically "better" or safer for any individual, but it is the reason researchers are studying whether retatrutide can push average weight loss higher than today's medications.
Ready to start?
$199 Skeptics’ Trial, see if it works for you
One month of medical-grade compounded semaglutide, the $119 doctor review, and a free B-12/lipotropic injection. No long-term commitment.
Start the 30-day trialWhat did the TRIUMPH-1 trial show?
According to an Eli Lilly press release dated May 21, 2026, the Phase 3 TRIUMPH-1 trial (NCT05929066, about 2,339 participants) reported that the 12 mg dose produced an average weight reduction of about 28.3% at 80 weeks on the efficacy estimand (roughly 25.0% on the treatment-regimen estimand), with 45.3% of participants losing at least 30% of body weight. A pre-specified extension in participants with a BMI of 35 or higher reported about 30.3%, or roughly 85 pounds, at 104 weeks. These are company-reported figures from a press release, not yet a peer-reviewed publication, and individual results in any future real-world use would vary.
Is retatrutide FDA-approved?
No. Retatrutide is investigational and is only available to people enrolled in the manufacturer's clinical trials. As of May 2026 there is no FDA filing yet. Secondary reporting suggests a submission could come around the end of 2026, with possible approval in the 2027 to 2028 window, but Lilly's own language notes there is no guarantee retatrutide will receive regulatory approval. Treat every date and price you see online as a projection, not a promise.
Why you should never buy "research peptide" retatrutide online
Because retatrutide is not approved, the only versions for sale online are grey-market "research chemicals" that are not made for human use, not quality-controlled, and not legal to use as medicine. Their identity, dose, sterility, and purity are unverified. Buying and injecting these is genuinely dangerous, and no legitimate, physician-led clinic will sell or recommend them. If a website offers to sell you retatrutide today, that is a red flag, not an opportunity.
What you can start today at New Hope Weight Loss
What a licensed clinic can legitimately offer right now is physician-supervised, compounded GLP-1 care. After a one-time $119 medical review with Dr. Sharma, eligible patients receive compounded semaglutide from $166 a month or compounded tirzepatide from $233 a month, with a $199 one-month Skeptics' Trial if you want to test the waters first. Compounded semaglutide and tirzepatide are prepared by licensed U.S. pharmacies and are not FDA-approved, not brand-identical, and not reviewed by the FDA for safety, effectiveness, or quality. Care is delivered in person in Orange County and by telehealth across California and additional states.
Frequently asked questions
Is retatrutide FDA-approved or available to buy?
No. Retatrutide is investigational. It is not FDA-approved, not sold by any pharmacy or clinic, and not offered at New Hope Weight Loss. The only legitimate way to receive it is by enrolling in the manufacturer's clinical trials. Any site selling 'retatrutide' is offering an unapproved grey-market product, which is unsafe and not something a licensed clinic will provide.
How much weight did people lose on retatrutide in trials?
Per Eli Lilly's May 21, 2026 press release, the Phase 3 TRIUMPH-1 trial reported about 28.3% average weight reduction at 80 weeks on the 12 mg dose (efficacy estimand), and a BMI-35-or-higher extension reported about 30.3%, roughly 85 pounds, at 104 weeks. These are company-reported figures from a press release, not a peer-reviewed publication, and real-world results would vary by person.
When will retatrutide be available?
There is no confirmed date. As of May 2026 there is no FDA filing; secondary sources suggest a possible submission around the end of 2026 and approval in roughly 2027 to 2028. Lilly itself states there is no guarantee retatrutide will be approved. Anyone promising a specific launch date or taking deposits now is not credible.
Can I get on a retatrutide waitlist at New Hope Weight Loss?
We do not take orders, deposits, or pre-orders for any investigational drug, including retatrutide, because that would not be legal or honest. What we can do is care for you now with physician-supervised compounded semaglutide or tirzepatide, and let you know as genuinely new options reach FDA approval.
What can I actually take for weight loss right now?
Today, eligible patients can start physician-supervised compounded semaglutide from $166 a month or compounded tirzepatide from $233 a month after a $119 medical review, with a $199 one-month trial option. These compounded medications are not FDA-approved or brand-identical, and your physician confirms whether they are appropriate for you.
This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.